RSV

Respiratory syncytial virus vaccine: vast blue ocean market

The burden of the disease is concentrated in immunocompromised individuals, lacking specific prevention and treatment methods, which has caused great clinical burden and social harm

RSV infection is epidemic among children under 5 years old, the elderly over 65 years old, and immunocompromised individuals. It causes tens of millions of infections and tens of thousands of deaths every year, resulting in a serious burden of disease.

Respiratory syncytial virus (RSV) is a worldwide epidemic virus and cause serious social burden. In decades, research results shown that the prefusion structure of the RSV F glycoprotein has more epitopes compared with postfusion RSV F.

Structure-based design of prefusion-stabilized RSV-F protein

The identification of Pre-F structure as the main target of neutralizing antibodies is important for the development of RSV vaccine.

Scale production

Stable and efficient process development is the prerequisite for large-scale production expansion, while production environment in compliance with laws and regulations is the key to ensuring drug declaration and listing. The company strictly follows GMP regulations in material management, institutional management, environmental management, equipment management, and quality management.

Rigorous production management ensures the integrated production of the whole RSV process, and ensures the basic principles of "safe, effective and controllable quality" for drug development. The independent platform capacity can meet the extreme requirement of completing a batch of production within 30 days.